Group 1 - The core viewpoint of the report emphasizes the potential of Novartis' Pluvicto in the nuclear medicine sector, particularly in the context of Radioligand Therapy (RDC), which is expected to drive growth in the nuclear medicine industry [4][15][26] - The report highlights that the nuclear medicine market in China is projected to reach 26 billion yuan by 2030, with significant growth potential driven by policy support and technological advancements [16][20] - The report identifies key companies to watch, including Dongcheng Pharmaceutical, which has a leading integrated drug innovation platform, and ASP Isotopes Inc., which focuses on high-value isotope production [4][32][37] Group 2 - The report provides a market review for the week of January 19-23, 2026, noting that the CITIC Pharmaceutical Index fell by 0.4%, while the pharmaceutical sector has seen a year-to-date increase of 6.5% [3][40] - The report indicates that the top-performing stocks in the pharmaceutical sector during this week included Changyao Holdings (+70.4%) and Hualan Biological Engineering (+32.2%) [5][55] - The report discusses the performance of various sub-sectors within the pharmaceutical industry, with pharmaceutical distribution and retail showing positive trends, while innovative drugs and CXO sectors lagged [5][43][66]

2025年进出口额近十万亿！ 1月19日，2025年广东进出口情况新闻发布会公布最新数据。过去一年，广东外贸顶住外部压力，进出口规模再创历史新高，总值达9.49万亿元人民币， 同比增长4.4%。这是自1986年以来，广东外贸规模连续第40年位居全国各省市首位，占全国外贸总值的20.9%，占比连续三年回升，对全国外贸增长的贡 献率高达24.1%，居全国第一。其中，进口3.46万亿元，增长7.8%；出口6.03万亿元，增长2.5%。 海关总署广东分署副主任张柯在会上介绍，广东外贸在2025年呈现出平稳向好的态势，四个季度规模逐季攀升，分别为2.13万亿、2.41万亿、2.47万亿、 2.48万亿元，均创下历史同期新高，展现出较强的韧性与潜力。（南都N视频APP·南都广州） 70城去年12月房价数据： 上海、宜昌新房价格同比、环比双涨 1月19日，国家统计局发布70城2025年12月房价数据。上海新建商品住宅价格在2025年12月以环比增长0.2%、同比增长4.8%居70城之首。此外，湖北宜昌 新建商品住宅价格环比微涨0.1%，同比微涨0.4%，房价保持相对稳定。 国家统计局数据显示，2025年12月份，70个大中 ...

Group 1 - The recent municipal economic work conference in Chengdu has outlined the direction and path for the city's economic work in the "14th Five-Year Plan" period, emphasizing the transformation of strategic deployment into high-quality regional development practices [1] - Sichuan Tianfu New Area aims to enhance enterprise services, optimize the development ecosystem, and accelerate the integration of science and industry to foster new growth drivers [1] - The focus is on project-driven growth and consumption stimulation, with efforts to improve the business environment and enhance communication between government and enterprises [1] Group 2 - Nureter Medical Technology, a leading nuclear medicine company in Chengdu's Shuangliu Economic Development Zone, is advancing in technology and industry implementation, with three key nuclear medicine products entering clinical stages [2] - Shuangliu is providing comprehensive support for enterprises, including project implementation and qualification processing, while also offering financial incentives for innovative drug clinical research [2] - The district is simplifying review and approval processes to facilitate business operations [2] Group 3 - Pengzhou is focusing on major projects and investments to ensure a strong start to the "14th Five-Year Plan," promoting a culture of project awareness and support throughout the community [3] - The city is committed to enhancing project planning and management, with a focus on attracting significant investments and ensuring the successful implementation of major projects [3] - Strategies include industry chain investment, scenario-based investment, and fund investment to drive the development of sustainable and tax-generating projects [3] Group 4 - Jianyang is positioning itself as an important node in the Chengdu-Chongqing economic circle, aiming to strengthen industrial support and enhance the quality of traditional industries while fostering new and future industries [4] - The city is focused on expanding its openness and promoting local products and culture to the market [4] - Efforts are being made to improve public service delivery and promote high-quality development in people's livelihoods [4]

Core Insights - The approval of GPN01530 for clinical trials in the U.S. marks a significant milestone for the company in the field of innovative pharmaceuticals, particularly in targeting fibroblast activation protein (FAP) for solid tumors [1] - GPN01530 is positioned as a potential game-changer in the diagnosis and treatment of solid tumors, with the ability to reshape the treatment landscape and provide new hope for patients globally [1][7] Group 1: Product and Technology - GPN01530 is not just another innovative nuclear drug; its unique application prospects and technological breakthroughs make it a core competitive asset for the company in the nuclear medicine sector [2] - The drug has shown superior performance in preclinical studies, demonstrating rapid tumor targeting, higher tumor uptake, and better pharmacokinetic properties compared to other FAP ligands [2][3] - GPN01530 has the potential to replace the current standard, 18F-FDG, in the market, setting a new benchmark for FAP-targeted drugs [2] Group 2: Market Potential - FAP is recognized as a promising target in nuclear medicine, with a high expression rate in 90% of epithelial tumors, making it suitable for various cancer types [3][4] - The global cancer incidence is projected to rise from 19.3 million in 2020 to 24.6 million by 2030, leading to an expanding drug market, with estimates suggesting a market size exceeding $200 billion in the U.S. by 2030 [4] - The compound is expected to benefit over ten million patients globally, significantly enhancing the standard of care for solid tumors [7] Group 3: Company Strategy and Globalization - The company has established a comprehensive global layout in the nuclear medicine industry, covering research, production, distribution, and sales [8] - With a robust pipeline of 16 innovative products in the registration phase, the company is one of the leaders in the nuclear medicine sector, particularly in the anti-tumor domain [8][11] - The recent establishment of a state-of-the-art production facility in Chengdu enhances the company's capability to meet global demand and supports its strategic goal of a fully integrated nuclear medicine supply chain [11][13] Group 4: Future Outlook - The company aims to leverage the "dual filing" international registration strategy to advance GPN01530's global development and registration efforts [14] - This approach not only enhances the company's clinical registration capabilities abroad but also allows for the integration of clinical trial experiences from mature markets back into domestic practices [14] - The successful development of GPN01530 could set a precedent for other Chinese innovative drugs to enter global markets, contributing to the global fight against cancer [14]

Group 1: Industry Developments - China's medical isotope self-sufficiency has made significant progress with the successful development of a complete eco-friendly industrial chain for iodine-131, including precursor preparation, reactor irradiation, and nuclear drug research [1] - The global nuclear medicine market is projected to reach nearly $39 billion by 2032, indicating strong growth potential in the sector [1] - The number of approved radiotherapy devices in China has exceeded 90, with over 70% being domestically produced, marking a shift from reliance on imports [2] Group 2: Company Highlights - China Tongyuan (01763) has signed a commercial cooperation agreement with Novartis for the radioligand therapy drug, providing a new treatment option for advanced prostate cancer patients [3] - Yuan Da Pharmaceutical (00512) has 15 innovative nuclear drugs in the registration phase, with a significant revenue increase of nearly 106% in its nuclear medicine segment, driven by the performance of its yttrium-90 microsphere injection [3] - Sidi Pharmaceutical (01244) has completed the first patient dosing of its radiolabeled drug, 177Lu-PSMA-3D1015, which aims to provide a safer and more effective treatment for metastatic castration-resistant prostate cancer [4]

Group 1: Industry Developments - China's medical isotope self-sufficiency has made significant progress, with the establishment of a complete eco-friendly autonomous industrial chain for iodine-131 production, including precursor preparation, reactor irradiation, and nuclear drug development [1] - The global nuclear medicine market is projected to reach nearly $39 billion by 2032, indicating strong growth potential in the sector [1] - The number of approved radiotherapy devices in China has exceeded 90, with over 70% being domestically produced, marking a shift from reliance on imports [2] Group 2: Company Updates - China National Nuclear Corporation's subsidiary, Atomic High-Tech Co., has signed a commercial cooperation agreement with Novartis for the radioligand therapy drug, which is the first approved targeted PSMA therapy for advanced prostate cancer in China [3] - Yuan Da Pharmaceutical has 15 innovative nuclear drugs in the R&D registration phase, with a significant revenue increase in its nuclear medicine segment, achieving approximately HKD 420 million in revenue, a year-on-year growth of nearly 106% [3] - Sillod Medical has completed the first patient dosing in a study for its radiolabeled drug, 177Lu-PSMA-3D1015, aimed at treating metastatic castration-resistant prostate cancer, positioning it as a potential best-in-class product [4]

Group 1: Medical Isotope Production - China National Nuclear Corporation (CNNC) has successfully developed a complete technology chain for the irradiation preparation of iodine-131, enhancing the self-sufficiency of medical isotopes in China [1] - The technology includes the preparation of precursor isotopes, reactor irradiation, and nuclear drug development, forming an environmentally friendly and autonomous industrial chain [1] - The successful production of high-purity tellurium-130 isotopes with over 99% abundance fills a gap in the domestic large-scale preparation of high-purity enriched tellurium isotopes [1] Group 2: Radiation Therapy Equipment and Drug Development - As of 2024, over 90 radiotherapy devices have been approved by the National Medical Products Administration, with more than 70% being domestic brands, significantly reducing reliance on imported equipment [2] - The development of new radiopharmaceuticals has accelerated, with over 200 pipelines entering clinical trials, introducing new isotopes like lutetium-177 and yttrium-90 for more precise cancer treatment options [2] Group 3: Corporate Transactions and Financial Updates - WuXi AppTec has completed the sale of its subsidiary, expecting a post-tax net profit of approximately 960 million yuan, which accounts for over 10% of the company's latest audited net profit attributable to shareholders [5][6] - Guolian Minsheng has terminated a 480 million yuan fund establishment transaction, with no adverse effects on the company's finances or shareholder rights [7] - Morning Paper Industry plans to sell all shares of a target company for 3.336 billion yuan [10] Group 4: New Technologies and Innovations - GAC Group's flying car, GOVY AirCab, has entered the airworthiness certification stage and is expected to be mass-produced by 2026, aiming to create a new mode of transportation that integrates air and ground travel [17] - China Tongyuan has signed a commercial cooperation agreement with Novartis for the radiopharmaceutical product, providing a new treatment option for advanced prostate cancer patients [18]

Core Viewpoint - China Tongfu (01763) announced a collaboration with Beijing Normal University to sign a patent transfer agreement and a cooperation agreement for the fluorine-18 labeled beta-amyloid imaging agent project, aimed at early diagnosis of Alzheimer's disease [1] Company Summary - The fluorine-18 labeled beta-amyloid imaging agent is a new drug developed by a team led by Professor Cui Mengchao from Beijing Normal University in collaboration with China Tongfu, possessing complete independent intellectual property rights [1] - The drug has shown significant improvement in clinical applications, demonstrating a notable reduction in non-specific uptake in brain white matter compared to similar products approved by the FDA [1] Industry Summary - The signing event marks a significant milestone in the collaboration between academia and industry, emphasizing the importance of transforming scientific research outcomes into national strategic productivity [1] - The nuclear medicine industry is currently experiencing a golden development period, with China Tongfu emerging as a core player in the field due to its deep industry experience and distinctive industrial characteristics [1] - Future collaborations will focus on accelerating the clinical transformation of core results and building a talent cultivation pathway, contributing to the global competition in new nuclear medicine technologies and supporting the high-quality development of China's nuclear medicine sector [1]

智通财经APP讯，中国同辐(01763)发布公告，2025年12月10日，原子高科股份有限公司(本公司旗下一 间于全国中小企业股份转让系统上市的附属公司)与北京师范大学在北京举办科技成果转化签约暨产学 研合作交流会，共同签署了氟[F]贝他嗪项目《专利转让协议》与《产学研合作协议》。 此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 氟[F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权的 一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著降 低的特点，优于已获FDA批准的同类产品。 ...

格隆汇12月11日丨中国同辐(01763.HK)公告，以下公告的中文原稿由中国同辐股份有限公司旗下一间于 全国中小企业股份转让系统上市的附属公司，原子高科股份有限公司(股份代号：430005)于中国境内发 布。 氟[F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权的 一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著降 低的特点，优于已获FDA批准的同类产品。 此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 2025年12月10日，原子高科股份有限公司(以下简称"原子高科")与北京师范大学(以下简称"北师大")在 北京举办科技成果转化签约暨产学研合作交流会，共同签署了氟[18F]贝他嗪项目《专利转让协议》与 《产学研合作协议》。 ...